Document Detail


Lorcaserin for the treatment of obesity.
MedLine Citation:
PMID:  21589947     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Obesity is a worldwide epidemic and there is an urgent need for the development of effective pharmacological therapies that target the metabolic and behavioral factors of body weight regulation. Serotonin (5-HT) has been implicated as a critical factor in the short-term (meal-by-meal) regulation of food intake and pharmaceutical companies have invested millions of dollars to discover and develop drug targets for the serotonergic pathway. Lorcaserin is a novel selective agonist of the 5-HT(2C) receptor for weight loss therapy. Preclinical and clinical studies indicate lorcaserin is well tolerated and not associated with cardiac valvulopathy or pulmonary hypertension suggesting that lorcaserin is a selective 5-HT(2C) receptor agonist and has little or no activation of the 5-HT(2B) and 5-HT(2A) receptors, respectively. Lorcaserin acts to alter energy balance through a reduction in energy intake and without an increase in energy expenditure and achieved the U.S. Food and Drug Administration guidelines for weight loss efficacy. It remains to be determined whether or not lorcaserin will be approved for the long-term management of obesity.
Authors:
L M Redman; E Ravussin
Related Documents :
14727767 - Effect of the volatile constituents isolated from thymus albicans, th. mastichina, th. ...
4905947 - Antimicrobial action of some citrus fruit oils on selected food-borne bacteria.
19209607 - Cardiac arrhythmia is the primary response of embryonic pacific herring (clupea pallasi...
10874557 - A second look at the relation between colorectal adenomas and consumption of foods cont...
18181217 - Nutrient intakes in women and congenital diaphragmatic hernia in their offspring.
14727767 - Effect of the volatile constituents isolated from thymus albicans, th. mastichina, th. ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  46     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2011-05-18     Completed Date:  2011-06-09     Revised Date:  2013-09-18    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  901-10     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.
Affiliation:
Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808, USA. leanne.redman@pbrc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Benzazepines / adverse effects,  pharmacology,  therapeutic use*
Clinical Trials as Topic
Humans
Obesity / drug therapy*
Serotonin 5-HT2 Receptor Agonists / therapeutic use*
Grant Support
ID/Acronym/Agency:
1P30 DK072476/DK/NIDDK NIH HHS; K99HD060762/HD/NICHD NIH HHS; R00 HD060762/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Benzazepines; 0/Serotonin 5-HT2 Receptor Agonists; 637E494O0Z/lorcaserin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Next Document:  New ??-adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease.